Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL
Phase 2
Terminated
- Conditions
- ASC-HASC-USLSIL
- Interventions
- Biological: PVX-2Other: Placebo
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- PapiVax Biotech, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03911076
- Locations
- 🇺🇸
Corpus Christi Women's Clinic (Elligo Health Research, Inc.), Corpus Christi, Texas, United States
🇺🇸Obstetrics & Gynecology Associates, Inc., Fairfield, Ohio, United States
🇺🇸Health Awareness, Inc., Port Saint Lucie, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath